NEW DELHI : Jubilant Life Sciences Ltd on Tuesday announced that its subsidiary, Jubilant Generics Ltd, has entered into a non-exclusive licensing agreement with Gilead Sciences, Inc, under which the Indian firm will get the right to manufacture and sell the potential covid-19 treating drug Remdesivir in 127 countries including India.
Under the licensing agreement, Gilead will transfer its technology for manufacturing Remdesivir to scale up production and enable expedited access of the medicine to Covid-19 patients upon approvals by regulatory authorities in respective countries, the company said in an exchange filing.